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Abstract
Poly (ADP-ribose) polymerase 1 (PARP-1) is a constitutive enzyme, the major isoform of PARP
family, which is involved in the regulation of DNA repair, cell death, metabolism, and
inflammatory responses. Pharmacological inhibitors of PARP provide significant therapeutic
benefits in various preclinical disease models associated with tissue injury and inflammation.
However, our understanding the role of PARP activation in the pathophysiology of liver
inflammation and fibrosis is limited. In this study we have investigated the role of PARP-1 in the
liver inflammation and fibrosis using acute and chronic models of CCl4-induced liver injury and
fibrosis, a model of bile duct ligation (BDL)-induced hepatic fibrosis in vivo, and isolated liver-
derived cells ex vivo. Pharmacological inhibition of PARP with structurally distinct inhibitors or
genetic deletion of PARP-1 markedly attenuated CCl4-induced hepatic cell death, inflammation,
and fibrosis. Interestingly, the chronic CCl4-induced liver injury was also characterized by
mitochondrial dysfunction and dysregulation of numerous genes involved in metabolism. Most of
these pathological changes were attenuated by PARP inhibitors. PARP inhibition not only
prevented CCl4-induced chronic liver inflammation and fibrosis, but was also able to reverse these
pathological processes. PARP inhibitors also attenuated the development of BDL-induced hepatic
fibrosis in mice. In liver biopsies of subjects with alcoholic or hepatitis B-induced cirrhosis,
increased nitrative stress and PARP activation was noted. These results, taken together, suggest
that the reactive oxygen/nitrogen species-PARP pathway plays a pathogenetic role in the
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development of liver inflammation, metabolism and fibrosis. Several PARP inhibitors are
currently in clinical trials for oncological indications. The current results indicate that liver
inflammation and liver fibrosis may be additional clinical indications where PARP inhibition may
be of translational potential.
Introduction
Globally, alcohol consumption, viral hepatitis and steatohepatitis are the leading causes of
chronic liver injury and inflammation, resulting in liver fibrosis, cirrhosis, eventually
culminating in the development of hepatocellular carcinoma. Liver fibrosis is the major
cause of morbidity and mortality amongst all chronic liver diseases(1). Liver fibrosis is
characterized by increased deposition of extracellular matrix (ECM) (2), resulting in the
disruption of cellular architecture. Derangement of the sinusoidal architecture not only
affects hepatocytes, but also exerts adverse effects on other non-parenchymal cell types such
as hepatic stellate cells (HSCs), myofibroblasts and endothelial cells, the function of which
would be essential in the maintenance of liver structure and function(3, 4).Activation of
HCSs plays a pivotal role in liver fibrogenesis, since these cells are the primary source of
ECM deposition upon liver injury(4). Although our knowledge on the pathomechanisms of
liver fibrosis has expanded over the past decade, the clinical options for the treatment of this
devastating condition remain severely limited.
Poly (ADP-ribose) polymerase1 (PARP-1) is a constitutively expressed primarily nuclear
enzyme, which plays important physiological roles in regulation of numerous cellular
processes, such as DNA repair and the maintenance of chromatin structure. In addition,
pathological over-activation of PARP-1, due to reactive oxygen and nitrogen species
formation, promotes cell death, and stimulates pro-inflammatory mediator production(5).
PARP-1 functions as a DNA damage sensor and signaling molecule, binding to both single-
and double-stranded DNA breaks. Upon binding to damaged DNA, PARP-1 forms
homodimers and catalyzes the cleavage of NAD+ into nicotinamide and ADP-ribose to form
long branches of ADP-ribose polymers on target proteins such as histones and PARP-1
itself, which results in cellular energetic depletion, mitochondrial dysfunction, and
ultimately necrosis. Numerous transcription factors (e.g. nuclear factor-κB), DNA
replication factors, and signaling molecules have also been shown to become poly(ADP-
ribosylated) by PARP-1(6, 7). By modulating these processed PARP inhibitors have been
shown to exert tissue protective and anti-inflammatory effects in animal models of ischemia-
reperfusion injury, circulatory shock, and various forms of inflammation(5, 8). It has also
been recently suggested that PARP-1 and PARP-2 (a minor isoform of PARP enzyme
family) play important roles in regulating important metabolic functions in rodents (e.g.
mitochondrial function/biogenesis, and adipogenesis) in various organ systems, including in
the liver, at least in part via modulation of NAD+ levels and consequently sirtuin 1
activity(9-12). Furthermore, PARP inhibition has recently been shown to improved
mitochondrial function (respiration, enzyme activity, reactive oxygen species defense) in
both C. elegans worms and in AML12 hepatocyte cell line, and promoted longevity in
worms(13).
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Recent studies have linked PARP-1 activation and up-regulation to the production of pro-
fibrotic markers such as connective tissue growth factor (CTGF) (14) and transforming
growth factor β (TGF-β)(15) in kidney tubular epithelial and vascular smooth muscle cells.
In this study, we have investigated the role of PARP-1 in liver inflammation, metabolism
and fibrosis using in vivo models of carbon tetrachloride (CCl4)-induced acute and chronic
liver injury, a model of bile duct ligation (BDL)-induced hepatic fibrosis, isolated liver-
derived cells, and samples from liver biopsies of cirrhotic human subjects. Our findings
unveil a pathogenic role of PARP-1 in liver inflammation, metabolism and fibrosis, and
indicate the potential therapeutic utility of PARP inhibitors for liver inflammatory diseases
and fibrosis.
Materials and Methods
Animals
All the animal protocols conformed to the National Institutes of Health (NIH) guidelines and
were approved by the Institutional Animal Care and use Committee of the National Institute
on Alcohol Abuse and Alcoholism ((Bethesda, MD, USA) and/or INSERM (Créteil,
France). 6- to 8-week-old male C57BL/6J mice were obtained from The Jackson Laboratory
(Bar Harbor, ME, USA). PARP1-/- mice on C57BL/6J were generated as previously
described(16). Male PARP1-/- mice and their wild type controls (PARP1+/+) were used in
the study (termed PARP-/- and WT/PARP+/+ mice in the figures).
Hepatic tissue samples from human subjects
Alcoholic and hepatitis B-associated cirrhotic liver samples (stage 3-4 fibrosis) were
collected from donor livers during liver transplantation from the Liver Tissue Cell
Distribution System (LTCDS), University of Minnesota. The LTCDs were supported by
NIH Contract #N01-DK-7-0004 / HHSN267200700004C. Additional information on the
sample preparation, age and gender of the donors is provided in the Supplemental Materials.
The details of the induction of liver injury and fibrosis by CCl4 and bile duct ligation
(BDL) and the treatment protocols are described in the Supplemental Methods.
The determination of liver function, histology and immunohistochemistry, quantitative
analysis of hepatic fibrosis are described in the Supplemental Methods.
The determination of hepatic PARP and myeloperoxidase activities, 4-hydroxynonenal (4-
HNE), 3-nitrotyrosine (3-NT), and hydroxyproline contents, real-time PCR, Western
immunoblot analysis are described in the Supplemental Methods.
Other procedures such as isolation and treatments of murine hepatic hepatocytes and
stellate cells, cell death determination by flow cytometer and activation of hepatic stellate
cells are also described in the Supplemental Methods.
Statistical analysis
All the values were represented as mean ± S.E.M. Statistical analysis of the data was
performed by ANOVA followed by Tukey's post-hoc test for multiple comparisons. The
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analysis was conducted using the GraphPad-Prism4 software. P<0.05 was considered
statistically significant.
Results
Acute CCl4 treatment exerts a time-dependent liver injury and PARP activation
To determine the onset of PARP activation and liver injury by CCl4, we performed a time
course experiment in an acute liver injury model induced by CCl4. CCl4 exerted a time-
dependent hepatic injury peaking as early as 48 hours, as indicated by increased serum ALT
activities (Suppl. Fig. 1A). This response was paralleled with enhanced hepatic nitrative and
oxidative stress, characterized by increased 3-nitrotyrosine (3-NT;Suppl. Fig. 1B) and 4-
hydroxynonenal (4-HNE;Suppl. Fig. 1C) content, and was also associated with a marked
increase in PARP activity in the liver tissue (Suppl. Fig. 1D,E).
Genetic ablation of PARP1-/- or its pharmacological inhibition protects mice against acute
CCl4 -induced liver injury
Acute liver injury was induced in either PARP1+/+(WT) or PARP1−/− mice with a single
injection of CCl4 as described in the supplemental methods section. Mice were sacrificed
and their hepatic tissues and serum were subjected to histological and biochemical
investigations 48 hours later. First, histological examination revealed massive inflammation
and necrosis (Suppl. Fig. 2A) and serum ALT levels revealed significant increase in WT
mice treated with CCl4, when compared with WT mice treated with vehicle (Suppl. Fig.
2B). Similar trend was observed with hepatic myeloperoxidase (MPO) activities, marker of
neutrophil infiltration (Suppl. Fig. 2C). Determination of inflammatory cytokines/
chemokines mRNA expression also revealed enhanced expression of TNF-α, IL1-β, MIP1-
α, MIP-2, MCP-1, respectively, in WT(PARP1+/+) mice treated with CCl4, when compared
to corresponding vehicle controls (Suppl. Fig. 2C). These phenotypic changes were smaller
in magnitude in PARP1-/- mice treated with CCl4 when compared to PARP1+/+ mice (Suppl.
Fig. 2A-D). Likewise, treatment with either of the two PARP inhibitors used (PJ34 or AIQ)
attenuated the CCl4-induced pathological alterations in WT mice (Suppl. Fig. 3A-C). Of
note the biochemical parameters measured in the vehicle-treated PARP1-/- mice were
comparable to those measured in WT(PARP1+/+) mice.
Genetic ablation of PARP1 protects against chronic CCl4-induced liver injury and
inflammation in mice
Chronic CCl4 treatment for 4 weeks (3 times/week) induced a significant degree of liver
injury, characterized by inflammation and necrosis evidenced by histological examination
(Fig. 1A) as well as elevated serum ALT levels (Fig. 1B). This liver injury was accompanied
by an increase in hepatic oxidative/nitrative stress markers (3-NT and 4-HNE) in the CCl4
treated group (Fig. 1C) and was also associated with an increase in the mRNA levels for
various pro-inflammatory cytokines and chemokines such as TNF-α, IL1-β, MIP1-α,
MIP-2, MCP-1 (Fig. 1D), respectively in the CCl4 treated group. The CCl4-induced
histological changes, oxidative/nitrative processes and pro-inflammatory responses were
markedly attenuated in PARP1-/- mice, indicating that PARP1 plays a pathogenic role in
CCl4 induced chronic liver injury (Fig. 1A-D).
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Absence of PARP1 protects against chronic CCl4 -induced liver fibrosis in mice
4 weeks of chronic CCl4 treatment induced development of significant liver fibrosis and
stellate cell activation, as evidenced by enhanced Sirius red staining (Fig. 2A) and
expression of alpha smooth muscle actin (α-SMA), markers of fibrosis and hepatic stellate
action, respectively (Suppl. Fig. 4A,B), and mRNA expression of the prototypical pro-
fibrotic markers such as collagen-1, connective tissue growth factor (CTGF), transforming
growth factor-β (TGF-β) and fibronectin (Fig. 2B). The liver fibrosis was also evidenced by
a significant increase in hydroxyproline levels, another marker of fibrosis (Fig. 2C). All of
the above-mentioned pro-fibrotic changes were significantly abrogated in PARP1-/- mice
(Fig. 2 and Suppl. Fig. 4A), suggesting that PARP1 plays a pathogenetic role in liver
fibrosis.
Pharmacological inhibition of PARP ameliorates CCl4-induced chronic liver injury,
inflammation, mitochondrial injury/dysfunction, metabolic dysregulation, and fibrosis
Similar to the effect of PARP1 genetic deficiency, treatment of mice with either of the two
structurally distinct PARP inhibitors used (PJ34 and AIQ), markedly attenuated the 4 weeks
of chronic CCl4 treatment-induced hepatic injury (evidenced by less histological injury and
reduced serum ALT levels) (Fig. 3A), as well as attenuated inflammation (diminished
hepatic myeloperoxidase (MPO) activity and reduced mRNA levels of the pro-inflammatory
cytokines/chemokines) (Fig. 3B).
Because, as mentioned in the introduction, PARP1 and PARP2 were recently implicated in
regulation of key metabolic functions, including adipogenesis in the liver, we investigated
the potential role of these effects in our 4 weeks CCl4 treatment-induced hepatic injury
model. Following CCl4 administration we could not find significant changes in liver lipid
accumulation as determining by Oil Red O staining and triglyceride content measurements
neither with or without treatments with PARP inhibitors AIQ and PJ34 (Suppl. Fig. 6A,B),
in contrast to the positive control livers from a chronic alcohol feeding model. Thus, the
beneficial effect of PARP inhibition on adipogenesis is not likely to be involved in the anti-
inflammatory and anti-fibrotic effects of PARP inhibitors observed in our study.
However, we found that chronic CCl4 treatment induced marked attenuation of
mitochondrial DNA (mtDNA) number and mitochondrial function measured by complex 1,
2 and 4 activities from the livers (Fig. 3C). These pathological changes were attenuated by
PARP inhibition.
Chronic CCl4 treatment was also associated with dysregulation of numerous genes involved
in metabolism (e.g. mitochondrial respiration, fatty acid oxidation, and glucose metabolism;
Fig. 3 D,E); and some of these pathological changes could be attenuated by PARP inhibitors
(Fig 3 D,E, and Suppl, Methods for description of genes), supporting an important role of
PARP in cellular metabolism, particularly in the mitochondria, which is in agreement with a
recent study using worms and AML12 hepatocytes (13).
Moreover, PARP inhibition attenuated the chronic CCl4 treatment-induced fibrosis and
stellate cell activation, as evidenced by attenuated Sirius red staining, reduced α-SMA
protein expression (Fig. 4A; Suppl. Fig. 4B) and mRNA expressions of the pro-fibrotic
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markers collagen-1, connective tissue growth factor, TGF-β, fibronectin and α-SMA protein
(Fig. 4B,C).
PARP inhibition or genetic deficiency of PARP1 protects against oxidant-induced cell
death in primary hepatocytes in vitro
To gain functional insight into the mode of the regulation of hepatocyte death by PARP1,
primary hepatocytes were isolated from WT (PARP1+/+) or PARP1-/- mice and treated with
H2O2 either in the absence or presence of PARP inhibitors. Then cell death was determined
by flow cytometry at 16h. Genetic deletion of PARP1 or its pharmacological inhibition
provided marked protection, predominantly by reducing the percentage of H2O2 induced
necrotic cell population (Fig. 5A), while only slightly affecting the percentage of the
apoptotic cell population (Fig. 5A).
PARP inhibition or genetic deficiency of PARP1 attenuates murine hepatic stellate cell
activation (HSC) in vitro
Activation of HSC and proliferation plays significant role in the liver fibrosis. Because
previous studies suggested that PARP1 activation leads to up-regulation of the production of
pro-fibrotic markers such as CTGF and TGF-β in kidney tubular epithelial and vascular
smooth muscle cells (14, 15), and we found attenuation of chronic CCl4-induced fibrosis
and expression of α-SMA by either PARP inhibition or deletion of PARP1, we examined
role of PARP1 in the process of HSC activation. HSCs were isolated from murine livers and
maintained for 7 days alone or in the presence or absence of PARP inhibitors, followed by
the determination of HSC activation markers by reverse transcription - quantitative PCR and
Western blotting. Both PARP inhibition with AIQ and PJ34 or genetic deletion of PARP1
significantly attenuated stellate cell activation, as evidenced by the significant attenuation of
the mRNA expression of the HSC activation markers α-SMA, CTGF, collagen-1,
fibronectin and TGFβ (Fig. 5B), and protein expression of α-SMA and collagen-1 (Fig.
5C). These data suggest that PARP1 plays an important role in the HSC activation.
Pharmacological inhibition of PARP reverses chronic CCl4-induced liver injury and
fibrosis
In the next series of experiments we have delayed the start of PARP inhibitor treatment to 4
weeks after the start of CCl4 administration. This is a time point when significant fibrosis
and stellate cell activation are already developed (Figs. 2,4; Suppl. Fig. 4). PARP inhibitor
treatment continued for an additional 4-week period in the presence of CCl4. Using this
protocol we were able to determine whether the development of fibrosis could be attenuated
when PARP inhibition is applied to an on-going pro-fibrotic process. Treatment of mice
with CCl4 for 8 weeks induced significant histopathological liver injury (Fig. 6A) and
fibrosis (Fig. 6B-D), characterized by a significant elevation in ALT levels (Fig. 6A),
increased Sirius red staining and α-SMA expression (Fig. 6B,C; Suppl. Fig. 5), as well as an
enhanced mRNA expression of the pro-fibrotic markers collagen-1, CTGF, TGF-β and
fibronectin (Fig. 6D) and hydroxyproline (Fig. 6E), all quantified at 8 weeks. When 4 weeks
of chronic CCl4 treatment was followed by 4 weeks of CCl4 in the presence of either of the
two PARP inhibitors (PJ34 or AIQ), the degree of liver injury, quantified at the end of the
experiments (8 weeks after the start of CCl4) was markedly attenuated compared to the
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group that received CCl4 for 8 weeks without PARP inhibitors (Fig. 6). These findings
indicate that PARP inhibition enhances the recovery of liner injury and attenuates the
development of further fibrosis even when it is administered at a stage of the disease where
established fibrosis is present and all relevant pro-fibrotic pathological processes continue.
Pharmacological inhibition of PARP attenuates the bile duct ligation (BDL)-induced liver
fibrosis
The limitation of the CCl4-induced hepatic fibrosis model is that it largely depends on
repetitive parenchymal injury evoked by multiple doses of CCl4. Therefore, we also
investigated the effects of PARP inhibition using the bile duct ligation (BDL) -induced liver
fibrosis model, which is characterized by less parenchymal injury (Fig. 7). Two weeks
following BDL there was marked increase in hepatic periductal fibrosis (Sirius red staining,
Fig. 7A) and mRNA expressions of various pro-fibrotic mediators (Fig. 7B). These
pathological changes were largely attenuated by treatment with PARP inhibitors (Fig.
7A,B), suggesting that PARP inhibition also exerts direct inhibitory effects on fibrotic
process, in addition to attenuating parenchymal injury.
PARP activity is elevated in human subjects with alcoholic and viral hepatitis-induced
cirrhosis
To determine whether human liver fibrosis is also associated with PARP-1 activation, we
have measured PARP-1 activation in hepatic tissues obtained from subjects with either
alcoholic- or viral hepatitis-induced cirrhosis (Fig. 8A). There was a significant increase in
PARP activity (∼3 fold) in these tissues, when compared with control subjects, which was
also associated with increased tissue levels of 3-NT (Fig. 8B). The increased PARP activity
was also corroborated by the detection of increased amounts of poly(ADPribosyl)ated
proteins in hepatic tissue lysates from subjects with liver fibrosis (Fig. 8C).
Discussion
The novel findings arising from our study are: (a) pharmacological inhibition of PARP or
genetic deletion of PARP1 ameliorates the acute and chronic CCl4 treatment-induced
oxidative stress, liver injury and inflammation in murine models; (b) pharmacological
inhibition of PARP or genetic ablation of PARP1 also attenuates liver fibrosis induced by
chronic CCl4 exposure; (c) inhibition of PARP or genetic deletion of PARP1 in hepatocytes
protects these cells from oxidant induced cell necrosis; (d) inhibition of PARP or genetic
deletion of PARP1 abrogates HSCs activation; (e) PARP inhibitors facilitate the recovery of
the liver after established liver fibrosis and also attenuate the development of fibrosis
induced by BDL, which is less dependent on parenchymal injury; (f) PARP inhibitors
facilitate the recovery of mitochondrial and various metabolic functions; (g) PARP1 activity
and PAR accumulation is markedly enhanced in hepatic tissues obtained from patients with
liver cirrhosis. These results indicate that oxidative stress and PARP1 play important
pathogenetic roles in liver injury, metabolism, inflammation and fibrosis.
Shiobara and colleagues have reported increased PARP1 expression, activity and PAR
accumulation in hepatic tissues from patients with liver cirrhosis and hepatocellular
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carcinoma (17), which is in agreement with our results. The pathogenetic mechanisms
involved in liver fibrogenesis, include oxidative stress and demise of hepatocytes,
involvement of an inflammatory cascade resulting in Kupffer cells and HSCs activation,
deposition of extracellular matrix, infiltration of inflammatory cells(3, 18). Given the
important role of PARP1 in the promotion of oxidative stress-induced cell death,
metabolic(9-12) and inflammatory processes(5-7) we hypothesized that PARP1 may
represent a key checkpoint in liver fibrosis, and its inhibition could be of therapeutic
potential. To gain functional insights on the role of PARP1 in hepatic inflammation,
metabolism, and fibrogenesis, we have employed a well-established liver injury models
induced by CCl4, and investigated whether PARP inhibition or genetic deletion of PARP1
ameliorates liver inflammation, extracellular matrix deposition and hepatic cellular injury
resulting in fibrosis.
CCl4 is metabolized in the liver by cytochrome P450 to generate corresponding free
radicals, that attacks the hepatocytes, induces the necrosis of parenchymal cells, augmenting
the inflammatory cascade in the liver(18). Consistent with previous studies, we observed
that CCl4 administration induced marked hepatic injury, oxidative stress, inflammatory cell
infiltration, and impaired liver function. In line with the aforementioned role of PARP1 in
mediating cell death and pro-inflammatory responses, here we found that loss of PARP1 or
its inhibition was associated with attenuated CCl4-induced hepatic injury and inflammation.
Hepatic fibrogenesis develops on the basis of pre-existent and continuous liver injury, in
part due to inflammatory cell infiltration(19). Chronic alterations in hepatic homeostasis are
believed to transduce various pro-inflammatory and pro-oxidant signals involved in
fibrogenesis(20). Activation of HSC are generally triggered by various cytokines/
chemokines and oxidants, including potent mitogens such as platelet derived growth factor
and epidermal growth factor(21, 22). Activated Kupffer cells also secret TGF-β, which
causes HSC activation(3). Recently, the pivotal role linking PARP1 activation and the pro-
fibrotic gene expression such as TGF-β and CTGF has been documented in vascular smooth
muscle cells and renal proximal tubular epithelial cells in vitro(14, 15). Furthermore, PARP1
inhibition has been found to abrogate, unilateral ureter obstruction induced CTGF
expression and renal interstitial fibrosis(14). CTGF and TGF-β have been also shown to be
pivotal mediators of hepatic fibrogenesis(23, 24). Consistent with these observations, we
have observed that PARP inhibition/genetic deletion abrogated the CCl4 induced HSC
activation and fibrogenesis.
Necrosis of hepatic parenchymal cells is both the consequence of liver injury, as well as an
active player in the promotion of local pro-inflammatory processes, which may contribute to
the activation of HSCs(2). Profibrotic responses can also be triggered by hepatocyte cell
death(25). Thus, pharmacological agents, which could selectively block the death of
hepatocytes, may also prevent Kupffer cell and HSC activation and consequent fibrosis. In
fact, our in vitro and in vivo experiments show that PARP inhibition or genetic deletion of
PARP1 attenuates hepatocyte necrosis and inflammatory response. It is likely that the net
effect of these processes is the interruption of multiple positive feed-forward cycles of pro-
inflammatory mediator production, pro-fibrotic mediator production, cell death and
oxidative and metabolic stress. The attenuation of oxidative and nitrative markers by PARP1
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deficiency and by PARP1 inhibitors, in fact, points to the existence of such feed-forward
cycles, and their interruption in the absence of functional PARP1. However, our results,
demonstrating that PARP inhibition also attenuates the BDL-induced hepatic fibrosis in
vivo, which is less dependent on parenchymal injury, coupled with attenuation of stellate cell
activation by genetic deletion of PARP1 or its pharmacological inhibition in vitro, strongly
suggest that PARP1 may also have direct regulatory effects on fibrotic processes,
independent on protecting from parenchymal injury and inflammation.
Recently studies also revealed an important role of PARP1, and the significantly less
abundant PARP2, in regulating cellular metabolism (e.g. mitochondrial function,
mitochondrial biogenesis, adipogenesis, among others) in multiple organ systems (including
in the liver) via modulation of cellular NAD+ supply, and consequently NAD+-dependent
deacetylase enzyme functions(9-12). Our observation that PARP inhibition attenuated the
CCl4-induced mitochondrial dysfunction, decline in mitochondrial number, dysregulation of
various key genes involved in metabolism, also in agreement with important role of PARP1
in metabolic regulation. Furthermore, these results also provide the in vivo proof of the
concept support for an elegant recent study demonstrating that PARP inhibition through
increased cellular NAD+ levels led to improved mitochondrial homeostasis in worms and
various mammalian cells, which was dependent on the activation of the worm sirtuin
homolog sir-2.1 and involved induction of mitonuclear protein imbalance, as well as
activation of stress signaling via the mitochondrial unfolded protein response with
consequent nuclear translocation and activation of FOXO transcription factor DAF-16,
promoting longevity(13).
PARP inhibitors also exert beneficial effects in preclinical and clinical models of cancers via
multiple mechanisms involving attenuation of cancer cell proliferation and migration,
decrease of angiogenesis, modulation of the tumor pro-inflammatory environment, and
promotion of cancer cell demise. The selective promotion of apoptotic cell death in cancer,
but not in normal cells by PARP inhibitors is based on the novel approach of “ synthetic
lethality ” in cancer therapy, because in certain cancers with selective defects in homologous
recombination repair (cancer cells frequently harbor defects in DNA repair pathways leading
to genomic instability) inactivation of PARP1, and possibly other minor isoforms of PARP,
directly causes cell death. Because of this, several classes of ultrapotent PARP inhibitors are
currently in clinical trials for the experimental therapy of various malignancies, including
triple-negative breast and ovarian cancers(26). The initial concern with chronic PARP
inhibition was the potential genomic instability and “ premature aging ” of cells. However,
the recent study demonstrating that reduced PARP activity extends lifespan in worms(13),
coupled with improved cardiovascular function and energetics in aging rats chronically
treated with PARP inhibitors(27, 28), argues that PARP inhibitors will be well tolerated
even during prolonged use in humans.
Our results, demonstrating the pivotal pathogenetic role of PARP1 in liver fibrosis, and the
potential of PARP1 inhibitors in restoring liver function after fibrosis, coupled with the
clinical availability of PARP1 inhibitors, suggest that re-purposing of PARP1 inhibitors for
the treatment of liver diseases associated with injury, inflammation and fibrosis may be of
future potential clinical utility.
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Fig. 1. Genetic ablation of PARP1 attenuates CCl4-induced chronic liver injury and inflammation
Livers of mice treated exposed to CCl4 for 4 weeks were excised and processed for histological and biochemical investigations.
Part (A) shows representative H&E stained images of liver sections. The scale depicts 100 μm. (B): Serum ALT levels in the
respective groups, n=6-8/group, *P<0.05 vs. WT (PARP1+/+)/PARP1-/- mice treated with vehicle; #P<0.05 vs. WT+CCl4. Part
(C) depicts oxidative/nitrative stress markers 4-HNE and 3-NT, n=8/group, *P<0.05 vs. WT/PARP1-/- mice treated with vehicle;
#P<0.05 vs. WT+CCl4. Part (D) shows the mRNA expression of pro-inflammatory cytokines (TNF- α, IL1- β) and chemokines
(MIP1- α, MIP2, MCP-1) in hepatic tissues following 4 weeks of CCl4 administration. n=8/group, *P<0.05 vs. WT/PARP1-/-
mice treated with vehicle; #P<0.05 vs. WT+CCl4.
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Fig. 2. Genetic ablation of PARP1 attenuates CCl4 induced chronic liver fibrosis
Part (A) shows representative images of paraffin embedded liver sections stained with Sirius red, a marker of fibrosis, and its
quantification from n=4-7 livers/group. The scale depicts 100 μm. Part (B) shows mRNA expression of fibrosis markers
(collagen-1, CTGF, TGF- β, and fibronectin) and part (C) denotes the levels of hydroxyproline in hepatic tissues from respective
groups of mice exposed to CCl4 for 4 weeks, n=8/group, *P<0.05 vs. WT(PARP1+/+)/PARP1-/- mice treated with vehicle; #
P<0.05 vs. WT+CCl4.
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Fig. 3. Pharmacological inhibition of PARP ameliorates CCl4-induced chronic liver injury, mitochondrial dysfunction, metabolic
dysregulation and inflammation
Part (A) shows representative H&E images from the respective groups (the scale depicts 100 μm) and serum ALT levels. Part
(B) shows hepatic myeloperoxidase (MPO) activities (marker of neutrophil infiltration) and mRNA expression of pro-
inflammatory cytokines (TNF-α, IL1-β) and chemokines (MIP1-α, MIP2, MCP-1) in hepatic tissues following 4 weeks of
chronic CCl4 exposure, respectively. Part (C) shows determination of mitochondrial DNA content(left) and quantification of
mitochondrial complex 1(I), 2(II) and 4(IV) activities(right). Part (D) shows expression of several mitochondrial respiration and
uncoupling genes by Realtime PCR. Part (E) shows quantification of fatty acid oxidation (left), fatty acid synthesis (middle) and
glucose metabolism (right) genes. All mRNA level is measured by Realtime PCR. n=6-12/group for experiments in panels A-E.
*P<0.05 vs. vehicle; #P<0.05 CCl4 vs. CCl4+PJ34/AIQ.
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Fig. 4. Pharmacological inhibition of PARP mitigates CCl4-induced chronic liver fibrosis
Part (A) shows representative images of paraffin embedded liver sections stained with Sirius red, a marker of fibrosis, and its
quantification from n=4-7 livers/group. The scale depicts 100 μm. Part (B) shows mRNA expression of fibrosis markers
(collagen-1, CTGF, TGF-β, and fibronectin) in the hepatic tissues following 4 weeks of chronic CCl4 exposure, n=8/group,
*P<0.05 vs. vehicle/PJ34/AIQ alone; #P<0.05 CCl4 vs. CCl4+PJ34/AIQ. Part (C) is a representative immunoblot of α-SMA
(marker of stellate cell activation) in the hepatic tissue lysates from the respective groups.
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Fig.5. PARP inhibition or genetic deficiency of PARP1 protects against oxidant induced cell death in primary mouse hepatocytes and
attenuates hepatic stellate cell activation
Part (A): isolated mouse primary hepatocytes from either WT (PARP1+/+) or PARP1-/- mice were treated with hydrogen
peroxide (H2O2; 3 mM) in the presence or absence of PARP inhibitors (AIQ and PJ34, 10 μM) for 16hr and normal cell
population and populations of cells exhibiting the marks of either necrotic or apoptotic death were simultaneously determined by
flow cytometry as described in Supplemental Methods. n=6-8/group, *P<0.05 vs. vehicle/PJ34/AIQ alone or PARP1+/+ cells
treated with vehicle; #P<0.05 H2O2 vs. H2O2+PJ34/AIQ, respectively. (B): Hepatic stellate cells were isolated from WT
(PARP1+/+) or PARP1-/- mice, and were maintained in the 10% FBS medium alone or with PARP inhibitors for 7 days and
mRNA expression (Fig. 5B) or protein (Fig. 5C) of stellate cell activation and fibrosis markers (collagen-1, CTGF, TGF-β, and
fibronectin) were determined, n=6-8/group, *P<0.05 vs. vehicle at Day 1 vs. Day 7 with or without PARP inhibitors; #P<0.05
vehicle at 7 days vs. AIQ/PJ34 at 7 days or PARP+/+ vs. PARP-/- cells at Day 7.
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Fig. 6. Pharmacological inhibition of PARP attenuates the established liver injury and fibrosis
Initially mice were treated with CCl4 or vehicle for 4 weeks. After reaching 4 weeks of CCl4 or vehicle treatment mice
continued to receive CCl4, vehicle, PARP inhibitors alone or PARP inhibitors in combination with CCl4 for additional 4 weeks.
(A): Representative H&E images of liver sections and serum ALT levels. The scale depicts 100 μm. Part (B) shows the
representative liver sections stained for Sirius red. The scale depicts 100 μm. Part (C) shows quantification of fibrosis based on
Sirius red staining from 4-7livers/group. Part (D) depicts mRNA expression of fibrotic markers (collagen-1, CTGF, TGF-β, and
fibronectin) and part (E) demonstrates the changes in hydroxyproline content in the hepatic tissues of mice exposed to CCl4 for
8 weeks or CCl4 for 8 weeks+PARP inhibitors (AIQ/PJ34) during the last 4 weeks of the CCl4 administration, n=8/group,
*P<0.05 vs. vehicle/PJ34/AIQ alone; # P< 0.05 CCl4 vs. CCl4 + PJ34/AIQ.
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Fig. 7. Pharmacological inhibition of PARP attenuates the bile duct ligation (BDL)-induced liver fibrosis
(A): Representative liver sections stained for Sirius red 2 weeks following the induction of BDL (left) and quantification of
fibrosis staining (right) from n=4-7 livers/group. The scale depicts 100 μm. Part (B) depicts mRNA expression of fibrotic
markers (collagen-1, CTGF, TGF-β, and fibronectin) in the hepatic tissues of mice exposed to BDL for 2 weeks or BDL for 2
weeks+PARP inhibitors (AIQ/PJ34) during the 2 weeks period, n=8/group, *P<0.05 vs. vehicle; # P< 0.05 BDL vs. BDL+ PJ34/
AIQ.
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Fig. 8. PARP activation in hepatic tissues from human subjects with alcoholic and viral hepatitis B-induced cirrhosis
Part (A) shows PARP activation in hepatic tissues obtained from human subjects with HBV-induced or alcoholic cirrhosis, n=6/
group, P<0.05 vs control subjects. Part (B) depicts the amounts of the oxidative/nitrative marker 3-NT levels in the respective
groups, n=6, P<0.05 vs. control subjects. Part (C) shows a representative immunoblot for poly(ADP-ribose) [PAR] proteins of
the hepatic tissue lysates from the respective groups. Note the enhanced PAR proteins in the samples obtained from subjects
with alcoholic cirrhosis or viral hepatitis.
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